CCL

Összesen 3 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM094352
035-os BibID:(cikkazonosító)5058 (scopus)85105433955 (wos)000662004700001
Első szerző:Géczi Dóra (biotechnológus)
Cím:Analysis of Circulating miRNA Profile in Plasma Samples of Glioblastoma Patients / Dóra Géczi, Bálint Nagy, Melinda Szilágyi, András Penyige, Álmos Klekner, Adrienn Jenei, József Virga, Zsuzsanna Birkó
Dátum:2021
ISSN:1661-6596 1422-0067
Megjegyzések:Background: Glioblastoma multiforme (GBM) is among the most aggressive cancers with a poor prognosis. Treatment options are limited, clinicians lack efficient prognostic and predictive markers. Circulating miRNAs?besides being important regulators of cancer development?may have potential as diagnostic biomarkers of GBM. (2) Methods: In this study, profiling of 798 human miRNAs was performed on blood plasma samples from 6 healthy individuals and 6 patients with GBM, using a NanoString nCounter Analysis System. To validate our results, five miRNAs (hsa-miR-433-3p, hsa-miR-362-3p, hsa-miR-195-5p, hsa-miR-133a-3p, and hsa-miR-29a-3p) were randomly chosen for RT-qPCR detection. (3) Results: In all, 53 miRNAs were significantly differentially expressed in plasma samples of GBM patients when data were filtered for FC 1 and FDR 0.1. Target genes of the top 39 differentially expressed miRNAs were identified, and we carried out functional annotation and pathway enrichment analysis of target genes via GO and KEGG-based tools. General and cortex-specific protein?protein interaction networks were constructed from the target genes of top miRNAs to assess their functional connections. (4) Conclusions: We demonstrated that plasma microRNA profiles are promising diagnostic and prognostic molecular biomarkers that may find an actual application in the clinical practice of GBM, although more studies are needed to validate our results.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
glioblastoma
circulating miRNA
blood plasma
network analysis
biomarker
NanoString
Megjelenés:International Journal Of Molecular Sciences. - 22 : 10 (2021), p. 1-20. -
További szerzők:Nagy Bálint (1956-) (molekuláris genetikus) Szilágyi Melinda (1984-) (biológus) Penyige András (1954-) (molekuláris genetikus) Klekner Álmos (1970-) (idegsebész) Jenei Adrienn (1978-) (biológus, kémikus) Virga József (1989-) Hádáné Birkó Zsuzsanna (1971-) (molekuláris genetikus)
Pályázati támogatás:2017-1.2.1-NKP-2017-00002
NKP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

2.

001-es BibID:BIBFORM088377
035-os BibID:(cikkazonosító)7522 (scopus)85092461194 (wos)000585658800001
Első szerző:Hádáné Birkó Zsuzsanna (molekuláris genetikus)
Cím:Novel molecularn markers in glioblastoma : benefits of liquid biopsy / Birkó Zs., Nagy B., Klekner Á., Virga J.
Dátum:2020
ISSN:1661-6596 1422-0067
Megjegyzések:Glioblastoma is a primary Central Nervous System (CNS) malignancy with poor survival. Treatment options are scarce and despite the extremely heterogeneous nature of the disease, clinicians lack prognostic and predictive markers to characterize patients with different outcomes. Certain immunohistochemistry, FISH, or PCR-based molecular markers, including isocitrate dehydrogenase1/2 (IDH1/2) mutations, epidermal growth factor receptor variant III (EGFRvIII) mutation, vascular endothelial growth factor overexpression (VEGF) overexpression, or (O6-Methylguanine-DNA methyltransferase promoter) MGMT promoter methylation status, are well-described; however, their clinical usefulness and accuracy is limited, and tumor tissue samples are always necessary. Liquid biopsy is a developing field of diagnostics and patient follow up in multiple types of cancer. Fragments of circulating nucleic acids are collected in various forms from different bodily fluids, including serum, urine, or cerebrospinal fluid in order to measure the quality and quantity of these markers. Multiple types of nucleic acids can be analyzed using liquid biopsy. Circulating cell-free DNA, mitochondrial DNA, or the more stable long and small non-coding RNAs, circular RNAs, or microRNAs can be identified and measured by novel PCR and next-generation sequencing-based methods. These markers can be used to detect the previously described alterations in a minimally invasive method. These markers can be used to differentiate patients with poor or better prognosis, or to identify patients who do not respond to therapy. Liquid biopsy can be used to detect recurrent disease, often earlier than using imaging modalities. Liquid biopsy is a rapidly developing field, and similarly to other types of cancer, measuring circulating tumor-derived nucleic acids from biological fluid samples could be the future of differential diagnostics, patient stratification, and follow up in the future in glioblastoma as well.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
glioblastoma
biomarker
Megjelenés:International Journal Of Molecular Sciences. - 21 (2020), p. 1-14. -
További szerzők:Nagy Bálint (1956-) (molekuláris genetikus) Klekner Álmos (1970-) (idegsebész) Virga József (1989-)
Pályázati támogatás:ÚNKP-20-4-II
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM098761
035-os BibID:(cikkazonosító)10005 (scopus)85114918353 (wos)000699643100001
Első szerző:Hutóczki Gábor (Ph. D. hallgató)
Cím:Novel Concepts of Glioblastoma Therapy Concerning Its Heterogeneity / Hutóczki Gábor, Virga József, Birkó Zsuzsanna, Klekner Almos
Dátum:2021
ISSN:1661-6596 1422-0067
Megjegyzések:Although treatment outcomes of glioblastoma, the most malignant central nervous system (CNS) tumor, has improved in the past decades, it is still incurable, and survival has only slightly improved. Advances in molecular biology and genetics have completely transformed our understanding of glioblastoma. Multiple classifications and different diagnostic methods were made according to novel molecular markers. Discovering tumor heterogeneity only partially explains the ineffectiveness of current anti-proliferative therapies. Dynamic heterogeneity secures resistance to combined oncotherapy. As tumor growth proceeds, new therapy-resistant sub clones emerge. Liquid biopsy is a new and promising diagnostic tool that can step up with the dynamic genetic change. Getting a 'real-time' picture of a specific tumor, anti-invasion and multi-target treatment can be designed. During invasion to the peri-tumoral brain tissue, glioma cells interact with the extracellular matrix components. The expressional levels of these matrix molecules give a characteristic pattern, the invasion spectrum, which possess vast diagnostical, predictive and prognostic information. It is a huge leap forward combating tumor heterogeneity and searching for novel therapies. Using the invasion spectrum of a tumor sample is a novel tool to distinguish between histological subtypes, specifying the tumor grades or different prognostic groups. Moreover, new therapeutic methods and their combinations are under trial. These are crucial steps towards personalized oncotherapy.
Tárgyszavak:Orvostudományok Elméleti orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
glioblastoma
liquid biopsy
invasion spectrum
oncotherapy
Megjelenés:International Journal Of Molecular Sciences. - 22 : 18 (2021), p. 1-15. -
További szerzők:Virga József (1989-) Hádáné Birkó Zsuzsanna (1971-) (molekuláris genetikus) Klekner Álmos (1970-) (idegsebész)
Pályázati támogatás:2017-1.2.1-NKP-2017-00002
Egyéb
ÚNKP-20-4
Egyéb
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1